P. Murali Doraiswamy, MBBS

Professor of Psychiatry and Behavioral Sciences
Director, Neurocognitive Disorders Program
Professor in Medicine
Faculty Network Member of the Duke Institute for Brain Sciences
Affiliate of the Duke Initiative for Science & Society
Campus mail 3550 Hosp South, Durham, NC 27710

Murali Doraiswamy MBBS FRCP is professor of psychiatry and professor in medicine at the Duke University School of Medicine where he is a highly respected physician neuroscientist at the Duke Institute for Brain Sciences. He specializes in the areas of brain health and personalized medicine and leads a clinical trials unit in developing novel personal diagnostics and therapeutics for cognitive enhancement and mental well-being. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and lectured at leading global forums to advance the forefront of neuroscience research.  Moreover as co-author of a popular book The Alzheimer’s Action Plan and co-author on more than 350 publications, he has received several awards in recognition of his scientific work and his involvement in pivotal landmark trials that have helped develop many modern neurotherapeutics. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain.

  

Education and Training

  • M.B.B.S., University of Madras (India), 1987

Grants

Publications

Bernath, Megan M., Sudeepa Bhattacharyya, Kwangsik Nho, Dinesh Kumar Barupal, Oliver Fiehn, Rebecca Baillie, Shannon L. Risacher, et al. “Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.” Neurology 94, no. 20 (May 19, 2020): e2088–98. https://doi.org/10.1212/WNL.0000000000009436.

PMID
32358220
Full Text

Arnold, Matthias, Kwangsik Nho, Alexandra Kueider-Paisley, Tyler Massaro, Kevin Huynh, Barbara Brauner, Siamak MahmoudianDehkordi, et al. “Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.” Nat Commun 11, no. 1 (March 2, 2020): 1148. https://doi.org/10.1038/s41467-020-14959-w.

PMID
32123170
Full Text

Blumenthal, James A., Patrick J. Smith, Stephanie Mabe, Alan Hinderliter, Kathleen Welsh-Bohmer, Jeffrey N. Browndyke, P Murali Doraiswamy, et al. “Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial.” J Am Geriatr Soc 68, no. 3 (March 2020): 559–68. https://doi.org/10.1111/jgs.16252.

PMID
31755550
Full Text

Sabbagh, M. N., M. Boada, S. Borson, P. M. Doraiswamy, B. Dubois, J. Ingram, A. Iwata, et al. “Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting.” J Prev Alzheimers Dis 7, no. 3 (2020): 171–78. https://doi.org/10.14283/jpad.2020.22.

PMID
32463070
Full Text

Sabbagh, M. N., M. Boada, S. Borson, M. Chilukuri, P. M. Doraiswamy, B. Dubois, J. Ingram, et al. “Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies.” J Prev Alzheimers Dis 7, no. 3 (2020): 158–64. https://doi.org/10.14283/jpad.2020.19.

PMID
32463068
Full Text

Horgusluoglu-Moloch, Emrin, Shannon L. Risacher, Paul K. Crane, Derrek Hibar, Paul M. Thompson, Andrew J. Saykin, Kwangsik Nho, and Kwangsik Alzheimer’s Disease Neuroimaging Initiative (ADNI). “Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways.” Sci Rep 9, no. 1 (October 10, 2019): 14498. https://doi.org/10.1038/s41598-019-50507-3.

PMID
31601890
Full Text

Nho, Kwangsik, Alexandra Kueider-Paisley, Shahzad Ahmad, Siamak MahmoudianDehkordi, Matthias Arnold, Shannon L. Risacher, Gregory Louie, et al. “Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.” Jama Netw Open 2, no. 7 (July 3, 2019): e197978. https://doi.org/10.1001/jamanetworkopen.2019.7978.

PMID
31365104
Full Text

Pontecorvo, Michael J., Michael D. Devous, Ian Kennedy, Michael Navitsky, Ming Lu, Nicholas Galante, Stephen Salloway, et al. “A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.” Brain 142, no. 6 (June 1, 2019): 1723–35. https://doi.org/10.1093/brain/awz090.

PMID
31009046
Full Text

Goudey, Benjamin, Bowen J. Fung, Christine Schieber, Noel G. Faux, Noel G. Alzheimer’s Disease Metabolomics Consortium, and Noel G. Alzheimer’s Disease Neuroimaging Initiative. “A blood-based signature of cerebrospinal fluid Aβ1-42 status.” Sci Rep 9, no. 1 (March 11, 2019): 4163. https://doi.org/10.1038/s41598-018-37149-7.

PMID
30853713
Full Text

Nho, Kwangsik, Alexandra Kueider-Paisley, Siamak MahmoudianDehkordi, Matthias Arnold, Shannon L. Risacher, Gregory Louie, Colette Blach, et al. “Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.” Alzheimers Dement 15, no. 2 (February 2019): 232–44. https://doi.org/10.1016/j.jalz.2018.08.012.

PMID
30337152
Full Text

Pages